In Silico Evaluation of Molecular Interactions for Parkinson’s Disease Drug Discovery
International Journal of Computational and Experimental Science and Engineering · 02.05.2026 · 12 (2)
DOI: 10.22399/ijcesen.5202 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Computational and Experimental Science and Engineering, online erschienen am 02.05.2026. Verfasst von Mohamed Benbouali und 4 weiteren Autor:innen. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Monoamine oxidase B (MAO-B) and Catechol-O-methyltransferase (COMT) inhibitors are crucial for the treatment of Parkinson’s disease (PD). Inhibition of these enzymes involves both natural and synthetic compounds. Passiflora incarnata serves as a significant source of natural bioactive molecules, primarily flavonoids (including Apigenin, Luteolin, Myricetin, Orientin, Quercetin, Kaempferol, Vitexin, Isovitexin, and Isoorientin) and alkaloids (such as Harman, Harmine, Harmol, Harmaline, Harmalol, 8-hydroxy Harmine, and Harmine N-oxide). Synthetic options include inhibitors such as Rasagiline, Selegiline, and Safinamide (targeting MAO-B), as well as Entacapone, Tolcapone, and Opicapone (targeting COMT).In this study, molecular docking was employed to identify ligands with optimal interaction energies for each enzyme and to characterize binding affinities, thereby aiding the potential design of new inhibitors. The docking analysis of natural compounds revealed that flavonoids exhibited the strongest affinities and consistent interaction patterns; notably, Myricetin demonstrated the most effective binding to both MAO-B and COMT. Among the synthetic compounds, Safinamide displayed the highest affinity for MAO-B, while Opicapone showed the highest affinity for COMT. These findings highlight the potential of both natural and synthetic inhibitors in reducing enzyme activity associated with PD, providing valuable insights for the development of more effective therapeutic agents.
Zitieren
APA
Benbouali, M., Khebouche, D., Ghomr, A., Missoum, N., & Lafri, I. (2026). In Silico Evaluation of Molecular Interactions for Parkinson’s Disease Drug Discovery. International Journal of Computational and Experimental Science and Engineering, 12(2). https://doi.org/10.22399/ijcesen.5202
Vancouver
Benbouali M, Khebouche D, Ghomr A, Missoum N, Lafri I. In Silico Evaluation of Molecular Interactions for Parkinson’s Disease Drug Discovery. International Journal of Computational and Experimental Science and Engineering. 2026;12(2). doi:10.22399/ijcesen.5202
BibTeX
@article{Benbouali2026,
author = {Benbouali, Mohamed and Khebouche, Djamila and Ghomr, Amina and Missoum, Noureddine and Lafri, Imene},
title = {In Silico Evaluation of Molecular Interactions for Parkinson’s Disease Drug Discovery},
journal = {International Journal of Computational and Experimental Science and Engineering},
year = {2026},
volume = {12},
number = {2},
doi = {10.22399/ijcesen.5202}
}
EUVIMED